FDA Approval of Eli Lilly’s Omvoh for Crohn’s Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists’ Brand Preferences Among the IL-23 Class, According to Spherix Global Insights
Despite greater physician pre-approval familiarity with Omvoh compared to J&J Innovative Medicine’s Tremfya, gastroenterologists favor Tremfya over Omvoh for Crohn’s disease. Exton, PA., January 29, 2025 – The FDA’s approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor available for patients with this challenging […]
Humira, Cosentyx gaining favor as treatments for hidradenitis suppurativa, but more support for biologics needed: Spherix
The introduction of biologic therapies for hidradenitis suppurativa (HS) has “revolutionized” treatment for the rare inflammatory skin condition, though there’s still plenty of progress to be made, according to Spherix Global Insights. A new white paper from the market research firm charts the impact of the introduction of biologics as a treatment for HS. First to earn […]
Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs
US nephrologists estimate half of all FSGS patients are not optimally managed, according to Spherix Global Insights. EXTON, PA., November 1, 2024 — Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney diseases with critical unmet therapeutic needs, according to Spherix Global Insights […]
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease
With few treatment options for patients, hematologists look to pipeline agents such as Johnson & Johnson’s nipocalimab and Novartis’ ianalumab to improve patient outcomes, according to Spherix Global Insights. EXTON, PA., July 24, 2024 – Autoimmune hemolytic anemia (AIHA) encompasses a group of rare disorders characterized by the destruction of red blood cells due to […]
Docs embrace Takeda’s Eohilia, creating competition for Sanofi, Regeneron’s blockbuster Dupixent
Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent and is delaying the use of Regeneron and Sanofi’s big blockbuster drug. The FDA rejected Eohilia, which Takeda called TAK-721 during development, in the chronic inflammatory disease eosinophilic esophagitis in […]
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
Impacts of Eohilia’s short-term 12-week label are still unfolding, but prescribers express interest in continuing consecutive treatment courses. EXTON, PA., July 18, 2024 – In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic esophagitis (EoE) in patients aged 11 and older. This […]
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
New prescriptions for Vabysmo and Eylea HD outpace reported current brand share, indicating further growth of the brands, according to Spherix Global Insights. EXTON, PA., June 24, 2024 – The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly shaping prescribing patterns. DME is the leading cause […]
Spherix Global Insights Appoints Leigh Anne Siino as Chief Revenue Officer
Leigh Anne Siino joins executive team to accelerate company’s revenue growth. EXTON, PA., June 17, 2024 — Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, is proud to announce the appointment of Leigh Anne Siino as Chief Revenue Officer (CRO). In this role, […]
Rheumatologists’ Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
As treatment strategies evolve, rheumatologists are refining SLE care with targeted biologics, driving a paradigm shift in lupus management, according to Spherix Global Insights. EXTON, PA., June 13, 2024 – Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of AstraZeneca’s Saphnelo (anifrolumab) for SLE, […]
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch
Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments. Exton, PA., June 12, 2024 – Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative colitis (UC) […]
